Eloralintide
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
The record documents three Lilly-funded studies in people: a single-injection placebo-controlled study in 48 healthy adults, a 12-week placebo-controlled study in 100 adults with overweight or obesity, and a 48-week randomized double-blind phase 2 trial in 263 adults, and all report more weight loss than placebo at higher doses. These studies are small and short, the full phase 2 paper could not be read, and a 2026 network meta-analysis rated the certainty of most comparisons low or very low. Every phase 3 trial on record is still recruiting.
Counted on the record: 17 human studies, 8 randomized trials, 730 participants, 3 animal studies, 10 lab studies.
Human-study sources are counted once each; reviews, databases, commentary, and the regulatory record are excluded. A complete participant total is unavailable because some human-study sources do not state an enrollment number.
- FDA
- In phase II & III
Reference only. Not medical advice.
Talk to a clinician before taking this, particularly if you have a heart condition. The Atlas can tell you what has been studied about Eloralintide. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.
Eloralintide is an experimental weight loss medicine that targets the amylin receptor in the body, a different target from the GLP-1 medicines already on the market. It is still being tested in clinical trials and is not an approved treatment. In a 48 week study in adults with obesity or overweight who did not have type 2 diabetes, people taking eloralintide lost between 9% and 20% of their body weight, depending on the dose, compared with under 1% on placebo. Scans in that study suggested most of the weight lost was fat rather than muscle. Longer and larger phase 3 trials are now underway in people with and without type 2 diabetes, and in people with related conditions such as knee osteoarthritis or sleep apnea, to learn more about how well it works and how safe it is over time.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Eloralintide is designed to activate the amylin receptor system, which helps regulate fullness and food intake, with a preference for the amylin 1 receptor over related receptors. Cell and animal studies suggest this signaling may reduce food intake and body weight, with more fat loss than lean tissue. Researchers have also proposed that amylin 1 activity could help explain lower resting heart rate and brief slowing of stomach emptying, but these mechanisms have not been directly confirmed in humans.
- Step 1Amylin receptor activationEloralintide is proposed to bind and activate the amylin 1 receptor, with much less activity at the related calcitonin receptor, based on cell studies.
- Step 2Brainstem signalingActivity at amylin receptors in brainstem regions is proposed to increase feelings of fullness and reduce food intake, though this circuit is not directly tested in people.
- Step 3Reduced food intakeIn rats, this signaling lowered food intake and body weight, an effect proposed to extend to the reported weight loss in human trials.
- Step 4Lean mass sparingWeight lost is reported as mostly fat in both rat studies and a human trial using body scans, with rat data suggesting less lean mass loss than another amylin drug.
- Step 5Slowed gastric emptyingA short-lived slowing of stomach emptying was measured after an early dose in one human study, proposed by researchers as a factor in gut tolerability, though it needs confirmation.
- Step 6Heart rate changeA reported lowering of resting heart rate in human trials is proposed, but not tested, to arise from amylin receptor activity in specific brainstem regions.
These steps describe a proposed pathway, not a fully proven one. Most receptor and food intake findings come from cell and rat studies, and researchers say there is no agreed selectivity threshold known to matter in people.
C-terminally amidated linear peptide of 37 amino acids, with non-coded residues at positions 11, 15 and 22; Cys2 and Cys7 joined by a methylene thioacetal bond; Lys26 acylated with a side chain of two gamma-Glu residues and a saturated linear 20-carbon diacid
The authors state that the methylene thioacetal bridge enhances chemical stability, and that the fatty diacid gives albumin binding to extend half-life
A proposed pathway, not a proven one
The theory that eloralintide works through selective amylin 1 receptor activation is still based largely on laboratory and rat data. Effects seen in humans, including lower resting heart rate and altered stomach emptying, are biologically plausible but have not been directly linked to that receptor mechanism. Eloralintide also appears to favor fat loss while preserving more lean mass, although the reason remains unclear. No human study has yet mapped the full pathway from receptor activation to these effects or established their long-term consequences.
Safety in detail
- Across early and phase 2 trials, the most common side effects were gastrointestinal symptoms and fatigue, with effects generally increasing at higher doses and appearing similar to existing GLP-1 medicines. A notable finding was a decrease in resting heart rate, while rare mood-related and serious events were reported but were not confirmed as treatment-related. Overall, the safety evidence is still limited, and larger, longer studies are needed to assess rare, long-term, cardiovascular, pancreatic, and gastrointestinal risks.
What people get wrong
Often saidEloralintide is an approved weight-loss medicine.
ActuallyEloralintide is still investigational. Phase 3 trials (the ENLIGHTEN programme) began in December 2025 and February 2026 and are still recruiting, main results expected 2028.
Often saidEloralintide is simply another GLP-1 drug.
ActuallyEloralintide is an amylin receptor agonist, a different class from GLP-1 medicines. It is described as selective for the amylin 1 receptor, unlike cagrilintide and petrelintide, which also activate the calcitonin receptor.
Often saidEloralintide acts only on the amylin receptor and not at all on the calcitonin receptor.
ActuallyIts selectivity is relative, not absolute. In Lilly's cell tests it fully activated the amylin 1, amylin 3 and calcitonin receptors, and was about 12 times more active at amylin 1 than at the calcitonin receptor. Reviewers note that amylin receptors are themselves built from the calcitonin receptor, and that no agreed selectivity threshold is known to matter in the body.
Often saidEloralintide has been proven to produce about 20% weight loss.
ActuallyIn a single 48-week phase 2 trial (T2D) average weight fell by 9% to 20% across dose groups, compared with 0.4% on placebo.
Often saidBecause it is selective, eloralintide causes no stomach or gut side effects.
ActuallyIn the phase 2 trial, nausea affected 11% to 64% of people, compared with 14% on placebo. Gut side effects rose with dose.
Often saidEvidence shows eloralintide is gentler on the gut than cagrilintide.
ActuallyThe comparison showing less conditioned taste avoidance than cagrilintide was done in rats, in short tests, by Lilly scientists. It has not been shown in head-to-head human trials.
Often saidEloralintide preserves muscle during weight loss.
ActuallyIn a commentary on the phase 2 trial, body scans were reported to show the weight lost was mostly fat. The finding of less lean mass loss than with cagrilintide came from rats, five per group, and lean mass includes bone and water as well as muscle.
Often saidEloralintide is safe for the heart because it lowers heart rate.
ActuallyEloralintide lowered resting pulse. In the phase 2 registry results, bradycardia was reported in 9 of 210 people on eloralintide and none of 53 on placebo. No amylin drug, including eloralintide, has been tested in a cardiovascular outcomes trial, so its effect on heart events is unknown.
Often saidEloralintide works better than other weight-loss drugs.
ActuallyOne network meta-analysis ranked higher-dose eloralintide highly, but it used only indirect comparisons from a single trial. The authors rated the certainty of most comparisons as low or very low and called the findings preliminary.
Often saidCombining eloralintide with tirzepatide is known to boost weight loss in people.
ActuallyGreater weight loss with the combination has been reported only in diet-induced obese rats. Human combination trials exist but have posted no results.
Often saidThe weight loss from eloralintide lasts after treatment stops.
ActuallyThe phase 2 trial had only ten weeks of follow-up after stopping. A commentary calls for longer trials that track weight maintenance and regain.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
How we got here
Discovery and patents
From 2021
- March 2021Patent priority dateMarch 2021 is the earliest priority date for Eli Lilly's patent family covering the compound later called eloralintide.
- March 2022US patent application filedEli Lilly filed a US patent application, later published as US 2022/0288168 A1, naming six inventors and describing the compound SEQ ID NO:2 for possible use in diabetes, obesity, dyslipidemia and NASH.
- September 2022Canadian patent application publishedEli Lilly's Canadian application CA3210140A1, sharing the March 2021 priority date, was published and listed as pending, describing the same compound under the label Compound II. It does not print the name eloralintide or the code LY3841136.
- October 2024US patent grantedEli Lilly was granted US patent US12115210B2, covering the compound SEQ ID NO:2 and methods of treating type 2 diabetes, obesity, dyslipidemia and NASH with it. Google Patents lists it as active with an anticipated expiration in 2042.
- June 2024Australian patent grantedEli Lilly was granted Australian patent AU2022228541B2, from the same priority date, covering a compound consisting of SEQ ID NO:2. It is listed as active, with an amended version published later, and does not print the name eloralintide.
Clinical development
From 2022
- March 2022Phase 1 study NCT05295940Eli Lilly began a phase 1 study of LY3841136 at three US sites, enrolling 148 people in single-dose and repeated-dose parts through January 2024. The trial is listed as completed, with no results posted.
- December 2025Discovery to proof of concept paperLilly scientists published a paper in Molecular Metabolism describing eloralintide's discovery, its selectivity for the amylin 1 receptor over the calcitonin receptor in lab and rat tests, and early human studies showing weight loss and a tolerable side effect profile. The authors note the human studies were small, short and funded by Lilly.
- November 2025Phase 2 trial results (NCT06230523)A 48-week phase 2 trial in adults with obesity or overweight, without type 2 diabetes, was published in The Lancet. It reported average weight loss of 9% to 20% across eloralintide doses against 0.4% on placebo, with nausea and fatigue the most common side effects.
- December 2025ENLIGHTEN-2 phase 3 trial startedEli Lilly began ENLIGHTEN-2 (NCT07282600), a phase 3 trial of eloralintide in adults with obesity or overweight and type 2 diabetes, planning about 1,035 participants with primary completion estimated for 2028.
- November 2025Lilly announces phase 2 resultsEli Lilly announced its phase 2 results for eloralintide in adults with obesity or overweight, presented at ObesityWeek and published at the same time in The Lancet, and said phase 3 enrollment would begin by the end of 2025. This is the sponsor's own news release.
- February 2026Phase 3 trial NCT07321886 startedA second phase 3 trial, NCT07321886, began in adults with obesity or overweight without type 2 diabetes, planning about 1,980 participants with primary completion estimated for 2028.
- September 2026Lilly announces eloraTZP phase 2 resultsEli Lilly announced it would present phase 2 results for eloraTZP, its name for an investigational combination of eloralintide and tirzepatide, in adults with obesity or overweight and type 2 diabetes, and said phase 3 trials of eloralintide were ongoing. This is the sponsor's own news release.
The people taking it
In online social forums, people report after a first week, appetite loss felt as "more of a mental block than physical", less stomach discomfort than on tirzepatide and no tiredness, and describe it as acting through the brain's fullness pathways. Users online say cagrilintide "buried them in fatigue" but eloralinitide did not. It is commonly used in combination with other GLP-1s.
No figure for the number of people using eloralintide exists outside clinical trials, as it is not approved. Registry records for completed Lilly studies list about 850 participants in total: 148 in the first phase 1 study, 263 in the phase 2 trial, 188, 128, 96 and 30 in four further phase 1 studies; not all of these received eloralintide, as several were placebo-controlled. Ongoing trials plan to enroll several thousand more, including five phase 3 trials with estimated enrollments of about 1,035, 1,980, 900, 800 and 900 adults, a phase 2 trial with 367 enrolled, and phase 2 trials planning about 200 and 400. Numbers of people using unapproved eloralintide outside trials are unknown.
Eloralintide is an experimental drug, so the people documented as receiving it are mainly clinical trial participants. In the 48-week phase 2 trial, 263 adults aged 18 to 75 with obesity or overweight plus at least one weight-related condition, and without type 2 diabetes, took part at US centres; they averaged 49 years old with an average body mass index of 39.1, and 78% were women and 78% were White. The first human study gave one injection to 48 healthy US adults with an average body mass index of 27.5, and a 12-week study enrolled 100 US adults with overweight or obesity and no diabetes. Other phase 1 studies enrolled Japanese adults with obesity or overweight in Japan, adults of Chinese descent with obesity or overweight at a site in Singapore, and adults aged 18 to 65 with a body mass index of 27 to 40 in the US. Current trials include adults with type 2 diabetes, adults with knee osteoarthritis or obstructive sleep apnea, adults already on an incretin medicine, and, in pharmacology studies, adults aged 18 to 85 with liver or kidney impairment. Most trials require a body mass index of 27 or higher. Nothing reliable is known about the demographics of people who report using unapproved eloralintide outside trials.
Eloralintide is not approved by any regulator; the FDA substance registry notes that its listing does not imply regulatory review or approval, and all registered studies are investigational. Early studies ran in the United States, Japan and Singapore. Phase 2 trials are listed in the United States, Argentina, Australia and Puerto Rico. Phase 3 trials list sites across the Americas, Europe, Asia and Oceania, including Argentina, Australia, Belgium, Brazil, Canada, China, Czechia, Denmark, Germany, India, Israel, Japan, Mexico, Poland, Puerto Rico, Romania, Slovakia, South Korea, Spain, Taiwan, the United Kingdom and the United States; a liver impairment study also lists Hungary. Outside trials, use of unapproved eloralintide is reported only in online personal accounts, with no reliable data on where.
What we do not know
- Will the weight loss seen in the 48-week phase 2 trial hold up in the larger, longer phase 3 trials now recruiting, and how well is weight kept off or regained after treatment stops, given that the phase 2 trial followed people for only ten weeks after stopping?
- How often do rare or serious harms occur, including possible long-term effects on the pancreas or heart? The phase 2 dose groups were too small to detect these.
- What causes the lower resting heart rate reported with eloralintide, and does it matter for health? The phase 2 registry results list slow heart rate in 9 of 210 people on eloralintide and none of 53 on placebo, and the brainstem explanation that has been proposed has not been tested.
- Does eloralintide lower the risk of heart attacks, strokes or other major heart and blood vessel events? No amylin receptor drug, including eloralintide, has yet been tested in a dedicated cardiovascular outcomes trial.
- Does eloralintide's preference for the amylin 1 receptor over the calcitonin receptor lead to real differences in weight loss or side effects in people, compared with dual agonists such as cagrilintide? Trials so far differ in design, length and who took part, and reviewers note that selectivity is not absolute.
- Does the lower taste avoidance seen in rats, which Lilly authors present as a sign of better gut tolerance, translate into fewer stomach and gut side effects in people? The rat tests were short.
- How does eloralintide affect stomach emptying over time, and is there any risk of gastroparesis? A paracetamol absorption test suggested only a short-lived effect, but the authors say this needs confirmation, and the phase 2 trial did not assess gut movement systematically.
- What explains the fatigue and the mood-related events reported in early trials, including the low mood that led some people at the highest dose to stop treatment in a 12-week study?
- Does the smaller loss of lean mass seen with eloralintide than with cagrilintide in obese rats also happen in people? The authors called the reason unclear.
- What do the reports of hair loss (15 of 210 on eloralintide versus none of 53 on placebo) and the serious adverse events listed in the phase 2 registry results mean? The registry does not say whether any of these were caused by the drug.
- How well does eloralintide work, and how safe is it, in people with type 2 diabetes? The phase 2 trial excluded them, and trials in this group have no posted results yet.
- Is eloralintide safe and effective in people when combined with tirzepatide or macupatide? Evidence that the combination adds to weight loss comes from rats, and the phase 1 combination studies have no posted results.
- Can eloralintide delay the onset of type 2 diabetes in people with prediabetes, which is being measured in an extension of a phase 3 trial?
- Does eloralintide ease knee osteoarthritis pain or reduce obstructive sleep apnea in people with obesity, beyond its effect on weight? Phase 3 trials of each are recruiting.
- How do liver impairment and severe kidney impairment change the amount of eloralintide that reaches the blood? Dedicated phase 1 studies are under way, with no results posted.
- Do the possible benefits proposed for long-acting amylin medicines in fatty liver disease, kidney complications of diabetes and hard-to-treat high blood pressure also apply to eloralintide? So far these have been described for the drug class, not shown for eloralintide.
At a glance
- Amino acid sequence
- γE-CNTATCATG-Orn-LAE-αMeF-LVRSSN-NMeN-FGPKLPPTEVGSNTY-NH2
- Molecular formula
- C201H319N49O65S2
- Molecular weight
- About 4526 g/mol, as computed
- CAS number
- 2883634-40-8
- UNII
- 73G3354J8W (FDA Global Substance Registration System). Having a UNII does not imply regulatory review or approval
- Development codes
- LY3841136, also listed as AMY-1176 in the FDA substance record
- Nonproprietary name
- ELORALINTIDE
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Eloralintide. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- What can go wrong. We have not written the risk line for this one. Read the safety section below rather than treating its absence as reassurance.
- Where we land. We have not taken a position on this yet.
Sources
In Lilly's cell tests, eloralintide fully activated all three human receptors and was about 12 times more active at the amylin 1 receptor than at the calcitonin receptor, and about 11 times more than at the amylin 3 receptor; at rat receptors it favored amylin 1 and amylin 3 over calcitonin. The authors note that no agreed selectivity threshold is known to matter in the body, and that it still needs measuring in a living body. In diet-induced obese male rats, about two weeks of repeated injections lowered food intake and body weight in step with dose, mostly as fat. Against cagrilintide, with five rats per group, food intake and fat fell similarly, but eloralintide cost significantly less lean mass (which can include muscle, bone and water); the authors call the reason unclear. In lean rats given one injection, next-day food intake fell similarly, but eloralintide produced significantly less conditioned taste avoidance three days later, which the authors use as a sign of gut tolerance; they suggest this may relate to cagrilintide's calcitonin receptor activity, while noting the tests were short and the two drugs last different lengths of time in the blood. These findings are in rats, not people. In the first human study, 48 healthy US adults with an average body mass index of 27.5 received one injection of eloralintide (36) or placebo (12). Its blood half-life was 12.9 to 15.3 days. 9 of the 36 on eloralintide reported side effects, nearly all mild; two at the highest dose had stomach or gut effects (one vomiting and nausea, one indigestion). Four weeks later, weight was 2.5% and 4.4% lower at the two highest doses, against a 0.6% gain on placebo, with no significant change at lower doses. The authors say the study was small and not limited to people with overweight or obesity, so weight loss was not well evaluated; Lilly funded it, and all authors were Lilly employees and shareholders. In a 12-week study of 100 US adults with overweight or obesity and no diabetes, weight fell 2.6% to 11.3% more than on placebo across four dose groups, more at higher doses, with a 0.2% gain on placebo; the difference was statistically clear at the three higher doses. 78 finished, and the authors say it was too small and short to show long-term weight loss; Lilly funded it and took part in its design, analysis and writing. The commonest side effects were lower appetite (19%), headache (12%), fatigue (11%) and COVID-19 (11%); diarrhea (10%), nausea (8%) and vomiting (4%) appeared only at higher doses, were mostly mild and led no one to stop. Four people had mood-related events, three with low mood and one reported as persistent depressive disorder; the three at the highest dose were taken off treatment, and symptoms cleared in 2 to 4 days. 11 people on eloralintide left because of adverse events, five with COVID-19; one serious event, a kidney injury, was judged unrelated by the investigator. Pulse fell from week 1 through week 12, by about 14 beats per minute at the highest dose against about 3 on placebo, with no symptoms of a slow heartbeat reported. Blood pressure was described as falling in both groups, with no clear dose link, but the page prints its week 12 changes as positive numbers, leaving the direction unconfirmed. In that study, a paracetamol absorption test showed somewhat less of it reaching the blood after the first higher-dose injection, back to baseline by week 12, with no significant change in time to peak. The authors read this as a short-lived effect on stomach emptying, unlike the delay expected from natural amylin and pramlintide, that may explain fewer stomach side effects; it still needs confirmation. A completed phase 1 study, NCT05295940, is registered only under the code LY3841136, with 148 participants at three US sites, March 2022 to January 2024, and no results posted: Part A gave single doses to adults with a body mass index of 18.5 to 32 and Part B repeated doses at 27 to 40, each blinded against placebo.
Billings et al.’s 48-week phase 2 trial enrolled 263 adults aged 18 to 75 with obesity or overweight plus at least one weight-related health condition, but without type 2 diabetes, at 46 US research centres; participants were randomly assigned, with neither they nor study staff knowing their assignment, to placebo or one of six eloralintide groups. Participants averaged 49 years old and a body mass index of 39.1; 78% were women and 78% were White. The trial was funded by Eli Lilly, and seven of the ten authors were Lilly employees; only the abstract could be read because access to the full paper was refused. The trial registry (NCT06230523), sponsored by Eli Lilly, describes 43 US sites and a trial period from February 2024 to August 2025; it lists the trial as completed, with results posted and 206 of 263 participants listed as finishing the study. At 48 weeks, average body weight fell by 9% to 20% across the eloralintide groups, with greater loss at higher doses, compared with 0.4% on placebo; the abstract labels these figures as its efficacy estimand and does not report how many participants stopped treatment. The posted results estimate that 53% to 91% of participants in the eloralintide groups lost at least 10% of body weight, compared with 13% on placebo, and that 72% to 98% lost at least 5%, compared with 31% on placebo. The abstract reports nausea and fatigue as the side effects most often reported on eloralintide: nausea affected 11% to 64% across the eloralintide groups versus 14% on placebo, and fatigue affected 0% to 46% versus 12%; it does not report serious side effects or how many participants stopped because of side effects. The posted registry results list serious adverse events in 11 of 210 participants given eloralintide and 3 of 53 given placebo over up to 58 weeks, and no deaths; reported events on eloralintide included two heart attacks, a stroke in the thalamus, Guillain-Barre syndrome, suicidal thoughts, and a kidney injury, and the registry does not say whether any were caused by the drug. Six participants on eloralintide and two on placebo left the study because of adverse events; other reported events included bradycardia in 9 of 210 participants on eloralintide and none of 53 on placebo, sinus bradycardia in 4 and none, hair loss in 15 and none, and nausea in 68 and 7, respectively.
In people with overweight or obesity given repeated eloralintide injections for 12 weeks, a 2025 conference abstract by Lilly researchers reports an average half-life of 13.9 to 15.8 days; it also states that, unlike other amylin drugs such as cagrilintide, eloralintide was designed to have minimal calcitonin activity in people, a design statement rather than a measured result.
In male rats made obese by diet, Lilly researchers report that eloralintide and tirzepatide each lowered food intake and body weight over two weeks, and that combining them, either started together or with eloralintide added to ongoing tirzepatide, lowered food intake, body weight and fat mass more than either drug alone. The conference abstract gives no animal numbers, doses or sizes of effect. These results come from rats, not people.
A 2026 network meta-analysis combined six trials involving 4,642 adults with overweight or obesity without diabetes; its only eloralintide data came from a 48-week phase 2 trial. In indirect comparisons, people in higher-dose eloralintide groups lost about 18% more body weight than those receiving placebo, second only to higher-dose injected amycretin and ahead of semaglutide and liraglutide; higher-dose eloralintide also ranked first among the drugs compared for kilograms lost (about 19.4 kg more than placebo), fall in body mass index (about 6.9 more than placebo), and fall in waist size (about 14.7 cm more than placebo). Higher-dose eloralintide raised overall stomach and gut side effects and nausea above placebo, whereas the lower-dose group did not; vomiting was higher in number but too imprecise to be sure, and eloralintide did not significantly increase stopping because of side effects; only higher-dose CagriSema did. The authors noted that the eloralintide trial enrolled people with a higher starting body mass index than some other trials and that many comparisons rested on single trials; they also judged the eloralintide trial to have some concerns about selective reporting, rated the certainty of most comparisons as low or very low, and called the findings preliminary.
A 2026 review classifies eloralintide as a selective amylin receptor agonist that targets amylin receptor 1, in contrast to dual agonists such as cagrilintide and petrelintide, which also activate the calcitonin receptor. The review summarizes a 48-week phase 2 trial in which higher doses reached nearly 20% weight loss and stomach and gut side effects rose with dose; nausea, fatigue, diarrhea and constipation were reported most often. The review’s text says about 10% of participants stopped treatment because of side effects, while its table gives 8% to 21%; it reports no pancreatitis, gallbladder inflammation or deaths, but these figures could not be checked against the full trial paper, which refused access. Reviewers caution that the label “selective” is not absolute, since amylin receptors are built from the calcitonin receptor paired with helper proteins and each drug may act differently across them; it remains unclear whether these differences in receptor targeting lead to meaningful differences in weight loss in people, because trials so far differ in design, length and who took part.
A 2026 review names eloralintide among the long-acting amylin-based drugs made possible by adding a fatty chain and by reversible binding to albumin, a blood protein. The reviewers propose that activity at the calcitonin receptor, how drug levels rise and fall, and which brain circuits are engaged may decide whether eating less reflects natural fullness or an unpleasant, aversive signal. This is a proposal from the review's abstract, which reports no eloralintide data of its own.
A 2026 literature review reports that early studies of eloralintide found decreases in body weight, pulse rate, blood pressure, inflammation markers and blood fats, with weight loss mostly as fat; the reviewers note that the decrease in pulse rate contrasts with the rise in heart rate seen with GLP-1 drugs. This evidence comes from small, short animal, phase 1 and phase 2 studies, and no amylin receptor drug, including eloralintide, has been tested in a dedicated cardiovascular outcomes trial, so whether it lowers major heart and blood vessel events remains unknown.
Eli Lilly is running a phase 2 trial, NCT06603571, in 367 adults with obesity or overweight and type 2 diabetes, testing eloralintide alone, tirzepatide alone, the two together, and placebo, at 52 sites in Argentina and the US. Its main measure is percent change in body weight at 48 weeks. The trial is active but no longer recruiting, its main data collection ended on 1 July 2026, and no results are posted yet.
Eli Lilly completed a phase 1 study, NCT06345066, in 96 adults with overweight or obesity at three US sites, giving eloralintide or placebo together with tirzepatide to check the safety and tolerability of the combination, from April 2024 to September 2025; it also measured weight change at week 42. The registry names the drug only by its code, LY3841136, and shows no posted results.
Eli Lilly completed a phase 1 study, NCT06297616, in 128 Japanese adults with obesity or overweight at three sites in Japan, from April 2024 to November 2025. Part A tested eloralintide alone against placebo, and Part B tested eloralintide, tirzepatide and the two together against placebo, looking at safety, blood levels and weight. The registry names the drug only by its code, LY3841136, and shows no posted results.
Eli Lilly completed a single-dose phase 1 study, NCT06916091, in 30 Chinese adults with obesity or overweight, defined as having all four grandparents of exclusive Chinese descent and born in China, at one site in Singapore from April to September 2025, to check safety, tolerability and blood levels against placebo. The registry shows no posted results.
Eli Lilly’s phase 3 trial NCT07321886 plans to enroll about 1,980 adults with obesity, or with overweight and a weight-related condition such as high blood pressure, and without type 2 diabetes, comparing four eloralintide dose groups with placebo. Its main measure is percent change in body weight at 64 weeks, and other measures include body fat, waist size, blood fats, blood pressure, inflammation, kidney function and quality of life; it started on 6 February 2026 and is recruiting at 158 sites in Argentina, Australia, Belgium, Brazil, Canada, China, Germany, India, Japan, Poland, Puerto Rico, South Korea, Taiwan, the United Kingdom and the United States, with main data collection estimated to finish in March 2028. The trial includes an extension in which participants with prediabetes continue for about two more years, measuring the time until type 2 diabetes develops, up to about week 191. Its registry record marks it as studying a drug under US Food and Drug Administration oversight, which describes how the trial is regulated and is not an approval; it also lists European Union Clinical Trials Information System number 2025-523657-34-00 and notes a data monitoring committee.
A phase 3 trial of eloralintide sponsored by Eli Lilly and Company (NCT07282600), named ENLIGHTEN-2 in its registry record, started on 15 December 2025 and is recruiting, with about 1,035 adults planned and primary completion estimated for January 2028; registry sites are listed in Argentina, China, Czechia, Germany, India, Japan, Mexico, Poland, Puerto Rico, Slovakia, South Korea, Spain, Taiwan and the United States, and no results are posted. ENLIGHTEN-2 enrolls adults with type 2 diabetes and a body mass index of 27 or higher whose diabetes treatment and body weight have been stable for 90 days before screening; people who took an amylin medicine, a GLP-1 or GIP/GLP-1 medicine, or insulin in the 90 days before screening cannot join, nor can people with type 1 diabetes. The randomized, double-blind study compares four eloralintide dose groups, given as injections under the skin, with placebo; its main measure is the percent change in body weight at week 64, and it also tracks body fat, waist size, HbA1c (a measure of long-term blood sugar), blood pressure, kidney function, eating control and quality of life. Taking part lasts about 75 weeks.
NCT07369011, named ENLIGHTEN-3 in its registry record, is a phase 3 master protocol sponsored by Eli Lilly and Company; it started on 10 February 2026, is recruiting about 800 adults, and has an estimated primary completion in March 2028. Sites are listed in Australia, Brazil, Canada, China, Germany, India, Japan, South Korea, Spain, Taiwan and the United States, and no results are posted. It comprises two separate randomized, double-blind, placebo-controlled studies in adults with moderate to severe obstructive sleep apnea and a body mass index of 27 or higher: one for people who cannot or will not use a positive airway pressure (PAP) machine, and one for people who have used PAP for at least three months and plan to continue; people with any type of diabetes cannot join. At week 64, the two main measures are percent change in body weight and change in the apnea-hypopnea index, which counts breathing pauses and shallow breaths during sleep; the studies also track daytime sleepiness, blood oxygen burden during sleep, blood pressure and quality of life. Taking part lasts about 76 weeks.
ENLIGHTEN-4 (NCT07353931), sponsored by Eli Lilly and Company, is a phase 3 master protocol comprising two separate randomized, double-blind, placebo-controlled studies of eloralintide for adults with painful knee osteoarthritis and overweight or obesity. It started on 9 February 2026 and is recruiting an estimated 900 adults; primary completion is estimated for March 2028, and no results are posted. Sites are listed in Argentina, Belgium, Brazil, Canada, China, Czechia, Denmark, Germany, Japan, Puerto Rico, South Korea, Taiwan, the United Kingdom and the United States. Participants must have a body mass index of 27 or higher and have tried at least once, without success, to lose weight through diet; people with any type of diabetes cannot join. The two main measures at week 64 are percent change in body weight and change in the pain part of the WOMAC, a standard osteoarthritis questionnaire; the studies also track physical function, stiffness, distance walked in six minutes and use of pain medicine. Taking part lasts about 75 weeks, including screening.
ENLIGHTEN-6 (NCT07392190), a phase 3 trial sponsored by Eli Lilly and Company, started on 10 February 2026 and is recruiting, with estimated enrollment of 900 adults and primary completion estimated for June 2028; its registry lists sites in Australia, Belgium, Brazil, China, Czechia, India, Israel, Japan, Mexico, Puerto Rico, Romania, Spain, Taiwan and the United States, and no results are posted. It enrolls adults whose obesity or overweight persists while they take a stable incretin medicine, which the record does not name: a body mass index of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure, abnormal blood fats, sleep apnea, heart disease or type 2 diabetes; people with and without type 2 diabetes can join, while recent use of a DPP-4 inhibitor, an amylin medicine or insulin rules people out. The randomized, double-blind study compares four eloralintide dose groups, given as injections under the skin on top of their incretin medicine, with placebo. Its main measure is percent change in body weight at week 64; it also tracks waist size, blood pressure, blood fats, kidney function and eating control, and participation lasts about 80 weeks.
Eli Lilly and Company ran the phase 1 trial NCT06916065 from April 2025 to January 2026 at three sites in the United States, enrolling 188 adults with overweight or obesity. The registry lists it as completed, but no results are posted there. The trial was open-label and not randomized: four groups received eloralintide with tirzepatide and two received eloralintide alone, all as injections under the skin. Its main measures were how much of each drug reached the blood, its peak level, and the number of people with side effects or serious side effects investigators judged related to the study drug. Participants were adults aged 18 to 65 with a body mass index from 27 to 40 and a stable weight; the trial excluded people with type 1 or type 2 diabetes, recent use of weight-loss medicines including GLP-1 medicines, conditions or surgery that change stomach emptying, and significant heart conditions such as second- or third-degree heart block or sick sinus syndrome.
PubChem lists eloralintide as compound CID 175663130, with molecular formula C201H319N49O65S2, a computed molecular weight of about 4526 grams per mole, and InChIKey RLBIFQNAUXZCQB-UHFFFAOYSA-N; it records CAS number 2883634-40-8 among its synonyms and links the compound to ChEMBL ID CHEMBL6068462 and NCI Thesaurus code C206906. PubChem’s computed structure leaves all 41 stereocenters undefined, so the entry does not specify which form each building block takes; by contrast, the FDA substance record names its amino acid building blocks, apart from glycine, in the L form.
Wikidata, a free community-edited database, describes eloralintide as a chemical compound with the alias LY3841136, and lists CAS Registry Number 2883634-40-8, UNII 73G3354J8W, KEGG ID D12886 and PubChem substance ID 497621299. None of these statements carries a supporting reference on the Wikidata page itself.
A 2025 conference abstract by Eli Lilly scientists describes eloralintide as a modified amylin peptide with a 20-carbon fatty diacid chain that bound amylin receptors in lab tests while remaining selective away from calcitonin receptors; the abstract gives no selectivity figures, and six of its nine authors are listed as Lilly employees. In rats, eloralintide stayed in the blood longer and was cleared more slowly than cagrilintide, which the abstract calls a non-selective amylin analog; it gives no half-life figures, animal numbers, or statistics. In lean rats, eloralintide reduced food intake and body weight about as much as cagrilintide but caused less conditioned taste avoidance (a rat test in which animals learn to avoid a flavor paired with feeling unwell), which the Lilly authors present as better gut tolerability; the abstract gives no animal numbers, doses, or statistics. In rats made obese by diet, eloralintide lowered body weight mainly through fat loss, with stronger effects on weight, food intake, and fat than cagrilintide, and cost less lean mass in head-to-head studies; the abstract gives no animal numbers or statistics (Briere et al., Diabetes 2025;74[Suppl 1]:849-P).
A 2026 conference abstract by Jinzi J. Wu and Chengfei Wu reports that, in lab cell tests, eloralintide switched on the human amylin 1 receptor at a concentration about 64 times lower than it needed for the human calcitonin receptor, which the authors describe as 64-fold selectivity. The same abstract reports that, in rats made obese by diet, oral ASC39, an experimental small molecule the authors call eloralintide-like, produced weight loss they describe as significant and as good as with injected eloralintide; the abstract gives no rat numbers and no statistics beyond calling the loss significant.
A 2026 commentary by An, Dai and Peng in The Innovation Medicine interpreted the 48-week phase 2 trial of eloralintide in 263 adults with obesity or overweight and without type 2 diabetes, reporting that dual-energy X-ray absorptiometry scans showed the weight lost was mostly fat; the commentary adds no new data, and its authors declared no competing interests. It states that eloralintide lowered resting heart rate, unlike the faster heart rate seen with GLP-1 and GLP-1/GIP medicines, and that one participant stopped treatment because of a slow heart rate that caused no symptoms; the authors propose, but did not test, that amylin 1 receptors in the area postrema and nucleus tractus solitarius may explain the lower heart rate. The commentary says nausea and vomiting were about as common as with existing GLP-1-based medicines, no drug-related bowel blockage or pancreatitis was reported, and fatigue contributed to some treatment stops; gut movement effects, including the risk of gastroparesis, were not systematically assessed, and the proposed link between fatigue, brainstem effects on alertness and rapid weight loss was not tested. It identifies small numbers in each dose group, too few to detect rare harms or long-term risks to the pancreas or heart, only ten weeks of follow-up after stopping, exclusion of people with type 2 diabetes, and no test alongside structured diet and exercise as trial limitations, and calls for larger, longer phase 3 trials that follow weight maintenance and regain.
Bailey, Flatt and Conlon’s 2026 review in Peptides lists eloralintide alongside petrelintide, Met-233 and AZD6234 as recently developed long-acting amylin medicines reported to have shown strong efficacy on their own in clinical trials, but the abstract gives no figures for eloralintide. The review says gut side effects, especially nausea similar to that reported for GLP-1 medicines, are common when people start amylin medicines but mostly settle with continued use; this is a class-level statement, not a finding specific to eloralintide. It traces amylin medicines to pramlintide, the first useful amylin receptor medicine, modeled on rat amylin, a form that does not clump, and found limited use alongside insulin; pramlintide acts in the brain to bring on fullness, and a newer understanding of amylin receptors, paired complexes involving the calcitonin receptor, and amylin’s structure helped the design of a second generation of long-acting amylin medicines that do not clump. The review says evidence is emerging that long-acting amylin receptor medicines may help people with fatty liver disease, kidney complications of diabetes and high blood pressure that resists treatment, but the abstract does not say these benefits have been shown for eloralintide.
NCT07215559 is a phase 2 trial sponsored by Eli Lilly and Company that started on 16 October 2025 and is recruiting an estimated 200 adults with obesity or overweight and type 2 diabetes; primary completion is estimated for March 2027. Sites are listed in Argentina, Australia, Puerto Rico and the United States, and no results are posted. The randomized, double-blind trial compares eloralintide alone, macupatide (LY3532226) alone, the two together, and placebo, all given as injections under the skin; its main measure is percent change in body weight at week 32, and it also tracks HbA1c, body mass index and fasting blood sugar, with participation lasting about 48 weeks. It takes adults aged 18 to 75 with type 2 diabetes, an HbA1c from 7.5% to 10.5% and a body mass index of 27 or higher, managed by diet and exercise, metformin or an SGLT2 inhibitor; people prescribed an amylin, GLP-1, GIP/GLP-1 or related medicine in the last six months, or insulin within the past year apart from short-term use, cannot join.
NCT07589608 is a phase 2 trial sponsored by Eli Lilly and Company whose official title describes it as phase 2b; it started on 15 May 2026 and is recruiting an estimated 400 adults with obesity or overweight and without type 2 diabetes, with primary completion estimated for September 2027. It runs under master protocol NCT06143956, all sites are in the United States, and no results are posted. The randomized, double-blind trial compares eloralintide alone at three dose levels, macupatide alone, three combinations of the two, and placebo, all given as injections under the skin; its main measure is percent change in body weight at week 36, and it also tracks weight at week 48 and the number of participants losing at least 5% and at least 10% of their weight, with participation lasting about 64 weeks. Beyond its master protocol’s rules, the trial excludes people with type 1 or type 2 diabetes, ongoing slow heart rhythm (bradyarrhythmia or sinus bradycardia), a resting pulse below 60 or above 100 beats a minute, or a history of pancreatitis; the registry record does not say why these limits were chosen.
A phase 1 trial sponsored by Eli Lilly and Company, NCT07401862, started on 10 February 2026 and is recruiting about 36 adults aged 18 to 85; its primary completion is estimated for March 2027. Sites are listed in Hungary and the United States, and no results are posted. The trial gives one injection of eloralintide (LY3841136) under the skin to people with mild, moderate or severe long-term liver impairment and to people with normal liver function, without blinding, and measures how much reaches the blood and its peak level up to day 71. Each person takes part for about 14 weeks, including a five-night stay at the research unit.
NCT07426380 is a phase 1 trial sponsored by Eli Lilly and Company that started on 24 February 2026 and is active but no longer recruiting; about 28 adults aged 18 to 85 are planned, with primary completion estimated for October 2026, and all sites are in the United States. The open-label, nonrandomized trial gives one under-the-skin injection of eloralintide (LY3841136) to people with severe kidney impairment, people with end-stage kidney disease on stable hemodialysis, and people with normal kidney function; it measures how much reaches the blood and its peak level up to day 71, and each person takes part for about 14 weeks, excluding screening. No results are posted.
The US Food and Drug Administration's Global Substance Registration System lists eloralintide with the unique ingredient identifier (UNII) 73G3354J8W and the designation ELORALINTIDE [USAN], its US adopted name; the page states that having a UNII does not imply any regulatory review or approval. The FDA substance record names eloralintide chemically as a chain of 37 amino acid building blocks ending in tyrosinamide, closed into a ring between the second and seventh building blocks by a thioether link; the chain includes uncommon building blocks: ornithine, alpha-methyl phenylalanine, N-methyl asparagine, and a lysine carrying a long fatty diacid chain, printed as 19-carboxy-1-oxononadecyl, attached through two gamma-glutamic acid links.